INTRODUCTION: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. Hidden access barriers may facilitate financial sustainability of pharmaceuticals in less affluent EU countries; however, they have rarely been documented in scientific publications. Our objective was to explore these access barriers for tumor necrosis factor (TNF) alpha inhibitors in rheumatoid arthritis (RA) in five Central and Eastern European countries. METHODS: A detailed interview guide was developed based on multi-stakeholder workshops and a targeted literature review. In each participant country 3-3-3-3 interviews with payers, rheumatologists, patients/patient representatives, and industry representatives were conducted. Responses were aggregated at a country level and validated by primary investigators in each country. RESULTS: Limited number of RA centers and consequently significant travelling time and cost for patients in distant geographical areas, uneven budget allocation among centers, limited capacity of nurses, narrowed patient population in national financial protocols compared to international clinical guidelines in initiating or continuing biologics, high administrative burden in prescribing biologics and limited health literacy of patients were the most relevant barriers to timely patient access in at least three participant countries. CONCLUSION: Assessing only the availability of TNF alpha inhibitors on the national list of reimbursed medicines provides limited information about real-world patient access to these medicines. Revealing hidden access barriers may contribute to initiate policy actions which could reduce inequity in patient access.

Center for Health Technology Assessment Semmelweis University Budapest Hungary

Department of Experimental and Clinical Pharmacology Medical University of Warsaw Warsaw Poland

Erasmus School of Health Policy and Management Erasmus University of Rotterdam Rotterdam Netherlands

Faculty of Medicine Slovak Medical University in Bratislava Bratislava Slovakia

Faculty of Technical and Human Sciences Sapientia University Tirgu Mures Romania

HealthQuest Sp zoo Sp k Warsaw Poland

National Institute of Rheumatology and Physiotherapy Budapest Hungary

OAKS Consulting s r o Prague Czechia

Syreon Research Institute Budapest Hungary

Syreon Research Romania Tirgu Mures Romania

Zobrazit více v PubMed

Balanescu A., Wiland P. (2013). Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation. Rheumatol. Int. 33 (6), 1379–1386.  10.1007/s00296-012-2629-4 PubMed DOI

Batko B., Stajszczyk M., Swierkot J., Urbanski K., Raciborski F., Jedrzejewski M., et al. (2019). Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Arch. Med. Sci. 15 (1), 134–140.  10.5114/aoms.2017.71371 PubMed DOI PMC

Baumgart D. C., Misery L., Naeyaert S., Taylor P. C. (2019). Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front. Pharmacol. 10, 279.  10.3389/fphar.2019.00279. eCollection 2019. PubMed DOI PMC

Brennan A., Bansback N., Reynolds A., Conway P. (2004). Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatol. (Oxford) 43 (1), 62–72. 10.1093/rheumatology/keg451 PubMed DOI

Codreanu C., Popescu C. C., Mogosan C. (2018). Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania. BioMed. Res. Int., 7458361.  10.1155/2018/7458361 PubMed DOI PMC

Degli Esposti L., Perrone V., Sangiorgi D., Sinigaglia L. (2019). Assessment of patients affected by rheumatoid arthritis eligible for biologic agents. Value Health 22, S433–S434.  10.1016/j.jval.2019.09.192 PubMed DOI

Domagała A., Dubas-Jakóbczyk K. (2019). Migration intentions among physicians working in Polish hospitals - Insights from survey research. Health Policy 123 (8), 782–789.  10.1016/j.healthpol.2019.06.008 PubMed DOI

Dougados M., Soubrier M., Antunez A., Balint P., Balsa A., Buch M. H., et al. (2014). Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 73 (1), 62–68.  10.1136/annrheumdis-2013-204223 PubMed DOI PMC

Economic Co-operation and Development (2018). Health at a Glance: Europe 2018: State of Health in the EU Cycle (Paris/EU, Brussels: OECD Publishing; ). Available at: https://ec.europa.eu/health/sites/health/files/state/docs/2018_healthatglance_rep_en.pdf (Accessed September 24, 2019).

Elek P., Takács E., Merész G., Kaló Z. (2017). Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy Plan 32, 349–358.  10.1093/heapol/czw133 PubMed DOI

European Commission (2013). Study on Corruption in the Healthcare Sector, HOME/2011/ISEC/PR/047-A2. Luxembourg: Publications Office of the European Union; Available at: https://ec.europa.eu/home-affairs/sites/homeaffairs/files/what-is-new/news/news/docs/20131219_study_on_corruption_in_the_healthcare_sector_en.pdf (Accessed October 9, 2019).  10.2837/58154 DOI

European Federation of Pharmaceutical Industries and Associations (2019). EFPIA Patient W.A.I.T. Indicator 2018 survey. IQVIA; Available at: https://www.efpia.eu/media/412747/efpia-patient-wait-indicator-study-2018-results-030419.pdf (Accessed September 24, 2019).

Gulacsi L., Brodszky V., Baji P., Kim H., Kim S. Y., Cho Y. Y., et al. (2015). Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev. Clin. Immunol. 11 (Suppl 1), S43–S52.  10.1586/1744666X.2015.1090313 PubMed DOI

Gulacsi L., Brodszky V., Baji P., Rencz F., Pentek M. (2017). The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Adv. Ther. 34 (5), 1128–1144.  10.1007/s12325-017-0538-3 PubMed DOI PMC

Győrffy Z., Dweik D., Girasek E. (2018). Willingness to migrate-a potential effect of burnout? A survey of Hungarian physicians. Hum. Resour. Health 16 (1), 36.  10.1186/s12960-018-0303-y PubMed DOI PMC

Inotai A., Petrova G., Vitezic D., Kaló Z. (2014). Benefits of investment into modern medicines in Central-Eastern European countries. Expert Rev. Pharmacoecon Outcomes Res. 14, 71–79.  10.1586/14737167.2014.868314 PubMed DOI

Inotai A., Csanádi M., Vitezic D., Francetic I., Tesar T., Bochenek T., et al. (2017). Policy practices to maximise social benefit from biosimilars. J. Bioequiv. Bioavail. 9, 467–472.  10.4172/jbb.1000346 DOI

Inotai A., Csanadi M., Petrova G., Dimitrova M., Bochenek T., Tesar T., et al. (2018). Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed. Res. Int. 2018, 9597362.  10.1155/2018/9597362 PubMed DOI PMC

Jönsson B., Hofmarcher T., Lindgren P., Wilking N. (2016). Comparator report on patient access to cancer medicines in Europe revisited. IHE Report. Lund: IHE The Swedish Institute for Health Economics; Available at: https://www.efpia.eu/media/412110/ihe-report-2016_4_.pdf (Accessed September 24, 2019).

Kaló Z., Landa K., Doležal T., Vokó Z. (2012). Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur. J. Cancer Care 21, 442–449.  10.1111/j.1365-2354.2012.01351.x PubMed DOI

Kaló Z., Annemans L., Garrison L. P. (2013). Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev. Pharmacoecon Outcomes Res. 13, 6735–6741.  10.1586/14737167.2013.847367 PubMed DOI

Kaló Z., Vokó Z., Östör A., Clifton-Brown E., Vasilescu R., Battersby A., et al. (2017). Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J. Mark Access Health Policy 5 (1), 1345580.  10.1080/20016689.2017.1345580 PubMed DOI PMC

Kamusheva M., Manova M., Savova A. T., Petrova G. I., Mitov K., Harsányi A., et al. (2018). Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Front. Pharmacol. 9, 795.  10.3389/fphar.2018.00795 PubMed DOI PMC

Kanavos P. G., Vandoros S. (2011). Determinants of branded prescription medicine prices in OECD countries. Health Econ. Policy Law 6, 337–367.  10.1017/S1744133111000090 PubMed DOI

Kawalec P., Stawowczyk E., Tesar T., Skoupa J., Turcu-Stiolica A., Dimitrova M., et al. (2017). Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Front. Pharmacol. 8, 288.  10.3389/fphar.2017.00288 PubMed DOI PMC

Kobelt G., Kasteng F. (2009). Access to innovative treatments in rheumatoid arthritis in Europe (Lund University, Sweden: European Federation of Pharmaceutical Industry Associations; ). Available at: http://www.comparatorreports.se/Access%20to%20RA%20Treatments%20October%202009.pdf (Accessed Nov 11, 2019).

Kostic M., Djakovic L., Šujić R., Godman B., Janković S. M. (2017). Inflammatory Bowel Diseases: Cost of Treatment in Serbia and the Implications. Appl. Health Econ. Hea 15, 85–93.  10.1007/s40258-016-0272-z PubMed DOI PMC

Kotulska A., Kucharz E. J., Wiland P., Olesinska M., Felis-Giemza A., Kopec-Medrek M., et al. (2018). Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. Reumatologia 56 (3), 140–148.  10.5114/reum.2018.76901 PubMed DOI PMC

Laki J., Monok G., Palosi M., Gajdacsi J. Z. (2013). Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin. Biol. Ther. 13 (3), 327–337.  10.1517/14712598.2013.735654 PubMed DOI

Nikiphorou E., Galloway J., van Riel P., Yazici Y., Haugeberg G., Ostor A., et al. (2017). The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. Clin. Exp. Rheumatol. 35 (3), 477–483. PubMed

Orlewska E., Ancuta I., Anic B., Codrenau C., Damjanov N., Djukic P., et al. (2011). Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med. Sci. Monit. 17, SR1–S13.  10.12659/msm.881697 PubMed DOI PMC

Ozierański P., McKee M., King L. (2012). Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? Health Econ. Policy Law 7, 175–195.  10.1017/S1744133111000168 PubMed DOI

Péntek M., Poor G., Wiland P., Olejarova M., Brzosko M., Codreanu C., et al. (2014). Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ. 15 (Suppl 1), S35–S43.  10.1007/s10198-014-0592-6 PubMed DOI

Pavelka K., Szekanecz Z., Damjanov N., Majdan M., Nasonov E., Mazurov V., et al. (2013). Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin. Rheumatol. 32 (9), 1275–1281.  10.1007/s10067-013-2240-4 PubMed DOI

Putrik P., Ramiro S., Kvien T. K., Sokka T., Pavlova M., Uhlig T., et al. (2014. a). Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198–206.  10.1136/annrheumdis-2012-202603 PubMed DOI

Putrik P., Ramiro S., Kvien T. K., Sokka T., Uhlig T., Boonen A. (2014. b). Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann. Rheum. Dis. 73 (11), 2010–2021.  10.1136/annrheumdis-2013-203819 PubMed DOI

Putrik P., Ramiro S., Keszei A. P., Hmamouchi I., Dougados M., Uhlig T., et al. (2016. a). Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann. Rheum. Dis. 75 (3), 540–546.  10.1136/annrheumdis-2014-206737 PubMed DOI

Putrik P., Ramiro S., Hifinger M., Keszei A. P., Hmamouchi I., Dougados M., et al. (2016. b). In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Ann. Rheum. Dis. 75 (4), 715–720.  10.1136/annrheumdis-2015-207738 PubMed DOI

Robertson J., Walkom E. J., Bevan M. D., Newby D. A. (2013). Medicines and the media: news reports of medicines recommended for government reimbursement in Australia. BMC Public Health 13, 489.  10.1186/1471-2458-13-489 PubMed DOI PMC

World Medical Association (2013). Declaration Of Helsinki – Ethical Principles For Medical Research Involving Human Subjects. The World Medical Association; Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (Accessed October 9, 2019).